{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-024496","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.507524+00:00","generated_at":"2026-06-27T07:08:08.286739+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon FY21 rev $6.3B, adj. EPS $6.54; provides FY22 guide rev $6.1-$6.4B, adj. EBITDA margin 34-36%","bullets":["FY21 revenue $6.3B (-3% as-reported vs 2020); GAAP diluted EPS $5.31; non-GAAP adj. diluted EPS $6.54.","Q4 revenue $1.604B (-1% YoY); adj. EBITDA margin 34.2% vs 42.2% in prior year.","Board declared $0.28 quarterly dividend payable March 17, 2022; record date Feb 28.","FY22 guidance: revenue $6.1-$6.4B; adj. EBITDA margin 34%-36%; interest ~$400M; tax rate 17.5%-19.5%.","Growth engines (Nexplanon, fertility, biosimilars) grew double digits; 4 business development deals since spin."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-024496","json":"https://secwatch.observer/filing/0001104659-22-024496.json","markdown":"https://secwatch.observer/filing/0001104659-22-024496.md","text":"https://secwatch.observer/filing/0001104659-22-024496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922024496/0001104659-22-024496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922024496/tm227000d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:08:08.286739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}